A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma
Latest Information Update: 01 Oct 2024
Price :
$35 *
At a glance
- Drugs YKST 02 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Excyte Biopharma
- 03 Sep 2024 New trial record
- 28 Aug 2024 Status changed from planning to recruiting.
- 17 Jun 2024 According to an Excyte Biopharma media release, dosing is completed in this trial.